Richard W. Compans

Richard W. Compans

Auto-generated profile, based on publicly available information

Richard W. Compans

Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA

Research Focus & Metrics

Academic Career Length

61Years (1966-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2011 in Nature
Verified
Journal Article
Open access
PDF file
SKSudhir Pai Kasturi
Sudhir Pai Kasturi
ISIoanna Skountzou
Ioanna Skountzou
RARandy Albrecht
Randy Albrecht
DKDimitrios Koutsonanos
Dimitrios Koutsonanos
THTang Hua
Tang Hua
BPBali Pulendran
Bali Pulendran
A feature of many successful vaccines is the induction of memory B cells and long-lived plasma cells that can secrete neutralizing antibodies for a lifetime. The mechanisms that stimulate such persistent responses remain poorly understood. Bali Pulendran and colleagues show that nanoparticles containing two Toll-like receptor ligands, proteins with important roles in innate immunity, can boost the magnitude and persistence of vaccine-elicited antibody responses in primates, improving vaccine-mediated protection against influenza virus. Here it is shown that nanoparticles containing two Toll-like receptor ligands can boost the magnitude and persistence of vaccine-elicited antibody responses in primates, improving vaccine-mediated protection against influenza virus. Many successful vaccines induce persistent antibody responses that can last a lifetime. The mechanisms by which they do so remain unclear, but emerging evidence indicates that they activate dendritic cells via Toll-like receptors (TLRs)1,2. For example, the yellow fever vaccine YF-17D, one of the most successful empiric vaccines ever developed3, activates dendritic cells via multiple TLRs to stimulate proinflammatory cytokines4,5. Triggering specific combinations of TLRs in dendritic cells can induce synergistic production of cytokines6, which results in enhanced T-cell responses, but its impact on antibody responses remain unknown. Learning the critical parameters of innate immunity that program such antibody responses remains a major challenge in vaccinology. Here we demonstrate that immunization of mice with synthetic nanoparticles containing antigens plus ligands that signal through TLR4 and TLR7 induces synergistic increases in antigen-specific, neutralizing antibodies compared to immunization with nanoparticles containing antigens plus a single TLR ligand. Consistent with this there was enhanced persistence of germinal centres and of plasma-cell responses, which persisted in the lymph nodes for >1.5 years. Surprisingly, there was no enhancement of the early short-lived plasma-cell response relative to that observed with single TLR ligands. Molecular profiling of activated B cells, isolated 7 days after immunization, indicated that there was early programming towards B-cell memory. Antibody responses were dependent on direct triggering of both TLRs on B cells and dendritic cells, as well as on T-cell help. Immunization protected completely against lethal avian and swine influenza virus strains in mice, and induced robust immunity against pandemic H1N1 influenza in rhesus macaques.

18 July 2010 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SSSean P Sullivan
Sean P Sullivan
DKDimitrios G Koutsonanos
Dimitrios G Koutsonanos
MMMaria del Pilar Martin
Maria del Pilar Martin
JLJeong Woo Lee
Jeong Woo Lee
VZVladimir Zarnitsyn
Vladimir Zarnitsyn
MPMark R. Prausnitz
Mark R. Prausnitz
Sullivan and his colleagues describe a novel microneedle patch-based system for vaccine delivery that targets the skin's antigen-presenting cells, providing improved immunogenicity and eliminating the hazards associated with using hypodermic needles. The group demonstrates the feasibility of this approach for influenza prophylaxis, whereby vaccine is encapsulated within microscopic polymeric needles that dissolve in the skin in minutes. Influenza prophylaxis would benefit from a vaccination method enabling simplified logistics and improved immunogenicity without the dangers posed by hypodermic needles. Here we introduce dissolving microneedle patches for influenza vaccination using a simple patch-based system that targets delivery to skin's antigen-presenting cells. Microneedles were fabricated using a biocompatible polymer encapsulating inactivated influenza virus vaccine for insertion and dissolution in the skin within minutes. Microneedle vaccination generated robust antibody and cellular immune responses in mice that provided complete protection against lethal challenge. Compared to conventional intramuscular injection, microneedle vaccination resulted in more efficient lung virus clearance and enhanced cellular recall responses after challenge. These results suggest that dissolving microneedle patches can provide a new technology for simpler and safer vaccination with improved immunogenicity that could facilitate increased vaccination coverage.

10 January 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JWJens Wrammert
Jens Wrammert
DKDimitrios Koutsonanos
Dimitrios Koutsonanos
GLGui-Mei Li
Gui-Mei Li
SESrilatha Edupuganti
Srilatha Edupuganti
JSJianhua Sui
Jianhua Sui
PWPatrick Wilson
Patrick Wilson
The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and monoclonal antibody responses induced by pandemic H1N1 infection in humans. Unlike antibodies elicited by annual influenza vaccinations, most neutralizing antibodies induced by pandemic H1N1 infection were broadly cross-reactive against epitopes in the hemagglutinin (HA) stalk and head domain of multiple influenza strains. The antibodies were from cells that had undergone extensive affinity maturation. Based on these observations, we postulate that the plasmablasts producing these broadly neutralizing antibodies were predominantly derived from activated memory B cells specific for epitopes conserved in several influenza strains. Consequently, most neutralizing antibodies were broadly reactive against divergent H1N1 and H5N1 influenza strains. This suggests that a pan-influenza vaccine may be possible, given the right immunogen. Antibodies generated potently protected and rescued mice from lethal challenge with pandemic H1N1 or antigenically distinct influenza strains, making them excellent therapeutic candidates.

24 October 2010 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SPSilke Paust
Silke Paust
HGHarvinder S Gill
Harvinder S Gill
BWBao-Zhong Wang
Bao-Zhong Wang
MFMichael P Flynn
Michael P Flynn
EME Ashley Moseman
E Ashley Moseman
UAUlrich H von Andrian
Ulrich H von Andrian
NK cells confer innate immune functions. Von Andrian and colleagues show that hepatic NK cells bearing CXCR6 receptors confer antigen-specific NK cell memory that is protective against various viruses. Hepatic natural killer (NK) cells mediate antigen-specific contact hypersensitivity (CHS) in mice deficient in T cells and B cells. We report here that hepatic NK cells, but not splenic or naive NK cells, also developed specific memory of vaccines containing antigens from influenza, vesicular stomatitis virus (VSV) or human immunodeficiency virus type 1 (HIV-1). Adoptive transfer of virus-sensitized NK cells into naive recipient mice enhanced the survival of the mice after lethal challenge with the sensitizing virus but not after lethal challenge with a different virus. NK cell memory of haptens and viruses depended on CXCR6, a chemokine receptor on hepatic NK cells that was required for the persistence of memory NK cells but not for antigen recognition. Thus, hepatic NK cells can develop adaptive immunity to structurally diverse antigens, an activity that requires NK cell–expressed CXCR6.

1 October 1974 in Virology
Verified
Journal Article
Closed access
PPPeter Palese
Peter Palese
KTKiyotake Tobita
Kiyotake Tobita
MUMasahiro Ueda
Masahiro Ueda
RCRichard W. Compans
Richard W. Compans

11 December 1998 in Science
Verified
Journal Article
Closed access
PDF file
Wei CaoWei Cao
Wei Cao
MHMichael D. Henry
Michael D. Henry
PBPersephone Borrow
Persephone Borrow
HYHiroki Yamada
Hiroki Yamada
JEJohn H. Elder
John H. Elder
MOMichael B. A. Oldstone
Michael B. A. Oldstone
A peripheral membrane protein that is interactive with lymphocytic choriomeningitis virus (LCMV) was purified from cells permissive to infection. Tryptic peptides from this protein were determined to be α-dystroglycan (α-DG). Several strains of LCMV and other arenaviruses, including Lassa fever virus (LFV), Oliveros, and Mobala, bound to purified α-DG protein. Soluble α-DG blocked both LCMV and LFV infection. Cells bearing a null mutation of the gene encoding DG were resistant to LCMV infection, and reconstitution of DG expression in null mutant cells restored susceptibility to LCMV infection. Thus, α-DG is a cellular receptor for both LCMV and LFV.